Efficiency of Potentiated Antibodies to Tumor Necrosis Factor-α (Artrofoon) in the Therapy of Patients with Rheumatoid Arthritis

  title={Efficiency of Potentiated Antibodies to Tumor Necrosis Factor-$\alpha$ (Artrofoon) in the Therapy of Patients with Rheumatoid Arthritis},
  author={V. I. Petrov and A. R. Babaeva and E. V. Cherevkova and O. I. Epstein and Svetlana Alexandrovna Sergeeva},
  journal={Bulletin of Experimental Biology and Medicine},
Antiinflammatory activity of a new preparation Artrofoon (antibodies against tumor necrosis factor-α in ultralow doses) and nonsteroid antiinflammatory drug diclofenac in patients with rheumatoid arthritis was compared in an open randomized trial. The course of treatment with Artrofoon more significantly improved clinical and laboratory signs in patients with the articular form of rheumatoid arthritis than diclofenac. 
[The phenomenon of release activity and the hypothesis of "spatial" homeostasis].
  • O. Epstein
  • Biology
    Uspekhi fiziologicheskikh nauk
  • 2013
It was shown that dilutions of parent substance prepared using this technology have one common peculiarity - they are capable to exert direct modifying effect on parent substance altering spatial structure ofparent substance and consequently its physical, chemical and biological properties.


Anti-cytokine therapy for rheumatoid arthritis.
DMARD-recalcitrant disease may become the main indication for the use of anti-TNF drugs in patients with RA and trials of IL-1 receptor antagonist show a relatively modest anti-inflammatory effect and a possible retardation of joint damage.
Role of cytokines in rheumatoid arthritis.
Overall these studies demonstrate that analysis of cytokine expression and regulation may yield effective therapeutic targets in inflammatory disease.